Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumours 5 Ovarian Neoplasms 3 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Previously Treated Non Small Cell Lung Cancer 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1 Muscle Invasive Bladder Cancer 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Advanced Solid Tumors 1

Interventions

Paclitaxel 12 atezolizumab 11 Gemcitabine 9 pembrolizumab 8 Injections 6 Carboplatin 6 Irinotecan 5 Docetaxel 5 Cetuximab 5 tocilizumab 4 navitoclax 4 Leucovorin 4 Fluorouracil 4 Bevacizumab 4 olaparib 3 cobimetinib 3 Oxaliplatin 3 Nivolumab 3 zolbetuximab 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 tivozanib 2 tislelizumab 2 spartalizumab 2 ridaforolimus 2 plocabulin 2 obinutuzumab 2 motesanib diphosphate 2 liposomal doxorubicin 2 linifanib 2 lenvatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumors × adavosertib × Clear all

NCT00648648 2023-09-21

MK-1775-001

Merck Sharp & Dohme LLC

Phase 1 Completed

206 enrolled 40 charts

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡